Skip to main content
Fig. 5 | BMC Complementary Medicine and Therapies

Fig. 5

From: A network pharmacology perspective for deciphering potential mechanisms of action of Solanum nigrum L. in bladder cancer

Fig. 5

The S. nigrum pathway constructed in the present study. Abbreviations: GF, growth factor; RTK, receptor tyrosine kinases; EGF, epidermal growth factor; EGFR, epidermal growth factor receptor; ERBB2, Erb-B2 receptor tyrosine kinase 2; Ras, HRas & KRas proto-oncogene; Raf-1, threonine-protein kinase Raf1; Elk-1, ETS transcription factor ELK1; c-Myc, MYC Proto-Oncogene; c-fos, AP-1 transcription factor subunit; Rb, protein phosphatase 1; E2F, retinoblastoma-associated protein; PI3K, phosphoinositide 3-kinase; mTOR, mechanistic target of rapamycin kinase; HIF-1α hypoxia-inducible factor 1 subunit alpha; NF-κB, nuclear factor kappa B; IκBα, NF-κB inhibitor alpha; AP-1, Jun & FOS proto-oncogene; Bcl-2, Bcl-2 apoptosis regulator; HK, hexokinase; VEGF, vascular endothelial growth factor A; eNOS, endothelial nitric oxide synthase; IL-6, interleukin 6; P53, tumor protein P53

Back to article page
\